Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.
| Image |  |
|---|---|
| Description | scientific article published on 19 September 2017 |
| Author/s |
author: Jonathan H Schatz Faiz Anwer |
| Publication date | September 19, 2017 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |